RTI Surgical competitors

Ms. Karen L. Zaderej is a Chief Executive Officer at AXOGEN, INC. and is based in United States.

Accredited public company director. Dynamic, creative, growth and success oriented leader. Proven experience building and leading an organization from distress to profitability while increasing shareholder value 5x in 24 months.

Timothy R. Wright is the President and CEO of M2Gen®. He was previously the Executive Vice President, Business Development, Strategy and Innovation at Teva. Mr. Wright is the founder and Chairman of the Drug Discovery and Development Institute for The Ohio State University Comprehensive Cancer Center, where he previously served as Director. He is a current a member of the Ohio State Innovation Foundation Board and the Ohio State School of Pharmacy External Advisory Board. Mr. Wright has served in executive leadership roles at several pharmaceutical firms, including Covidien, Elan, and DuPont Merck. He holds a B.Sc. from The Ohio State University.

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors. Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

Mr. Dominick C. Colangelo joined Promedior in December 2008 with fifteen years of pharmaceutical industry experience, including nearly a decade with Eli Lilly and Company. During his career, Mr. Colangelo has held a variety of executive positions of increasing responsibility in finance, product development, pharmaceutical operations, and corporate business development. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as an international tax attorney in the finance organization and as Director of Strategy and Business Development for Lilly’s Diabetes and Growth Disorders Product Group. He also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the State University of New York at Buffalo and a J.D. degree from the Duke University School of Law.

Jean-Claude Dubacher is Chairman and CEO of B. Braun of America Inc., which includes B. Braun Medical Inc., B. Braun Interventional Systems, Aesculap® and CAPS®. Mr. Dubacher joined B. Braun in August 2019 as President, B. Braun Medical Inc., and has served as Chairman and Chief Executive Officer of B. Braun Medical Inc. since January 1, 2020. Dubacher’s experience in healthcare spans more than 15 years in consulting and corporate roles including strategy, commercial, supply chain and manufacturing. Prior to joining B. Braun, Dubacher led commercial operations for the Surgical Ophthalmology Division of Johnson & Johnson (formerly Abbott Medical Optics) in Europe. Throughout his career, Mr. Dubacher has demonstrated a passion for focusing on customer needs and supporting people to be successful in developing, manufacturing, marketing, and selling products and services that benefit patients. Dubacher holds a Doctorate Degree in law (Dr. iur.) from the University of Zurich in Switzerland, and an MBA from Harvard Business School. He is a board member for the German American Chamber of Commerce.

John Ducker is a Plant Manager at Fresenius SE Group, President/CEO at Fresenius Kabi USA, and Director at FRANCESCA'S HOLDINGS CORP. He has worked as Board Member at FRESENIUS KABI ONCOLOGY LIMITED, President/CEO at App Pharmaceuticals Inc., and Board Member at Dabur Pharma Co. Ltd. John studied at University of Cambridge.

Avi Pelossof was appointed Global President of our infectious disease business unit in March 2013, after serving as Vice President of that business from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008. Mr. Pelossof has more than 20 years of experience in diagnostics, global health and international finance, including senior roles at Chembio Diagnostic Systems, a manufacturer of diagnostic tests for infectious diseases, and Citigroup.